Total treatment costs by stage at diagnosis are estimated for a sample of breast cancer patients.
At 4 years, stage 4 cancers emerge as being more expensive to treat than those at earlier stages, although this difference fails to achieve significance when expected lifetime costs are considered.
The inclusion of treatment cost estimates in a screening model indicates that screening may increase expected treatment costs by a marginal amount, although the model also suggests that the cost-effectiveness ratio of breast cancer screening might be better than had originally been thought.
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Traitement, Stade clinique, Coût, Homme, Royaume Uni, Europe, Analyse coût efficacité, Dépistage, Economie santé, Glande mammaire pathologie
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Treatment, Clinical stage, Costs, Human, United Kingdom, Europe, Cost efficiency analysis, Medical screening, Health economy, Mammary gland diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0305552
Code Inist : 002B20E02. Création : 27/11/1998.